Mr. Zeeshan Saeed reports

QUANTUM BIOPHARMA ANNOUNCES CLOSING OF DEBT SETTLEMENT

Quantum Biopharma Ltd. has provided the following corporate updates.

The company is pleased to announce that, further to its press release of July 20, 2026, it has closed the settlement of $123,487.43 owing to arm's-length creditors and insiders of the company through the issuance of Class B subordinate voting shares in the capital of the company. The shares were issued at a deemed price of $3.99 per Class B share, representing the closing price of the Class B shares on the Canadian Securities Exchange on the trading day immediately prior to the date of closing. In full settlement of the debt, the company issued an aggregate of 30,948 Class B shares to the creditors.

About Quantum Biopharma Ltd.

Quantum Biopharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum Biopharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum Biopharma invented unbuzzd and spun out its over-the-counter version to a company, Unbuzzd Wellness Inc., led by industry veterans. Quantum Biopharma retains ownership of 19.84 per cent (as of March 31, 2026) of UWI. The agreement with UWI also includes royalty payments of 7 per cent of sales from Unbuzzd until payments to Quantum Biopharma total $250-million. Once $250-million is reached, the royalty drops to 3 per cent in perpetuity. Quantum Biopharma retains 100 per cent of the rights to develop similar product or alternative formulations specifically for pharmaceutical and medical uses.

We seek Safe Harbor.